 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration FDA has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma MCL and for treatment of chronic lymphocytic leukemiasmall lymphocytic lymphoma CLL. Cirmtuzumab is an investigational anti-ROR1 monoclonal antibody being evaluated in clinical trials in patients with MCL, CLL and HER2-negative breast cancer. 